{
  "id": 10916386,
  "title": "UBS resumes IQVIA stock coverage with buy rating on bookings outlook",
  "url": "https://urgent.news/2026/09/30/ubs-resumes-iqvia-stock-coverage-with-buy-rating-on-bookings-outlook",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-30T10:22:47.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/ubs-resumes-iqvia-stock-coverage-with-buy-rating-on-bookings-outlook-93CH-4924576"
  },
  "original_language": "en",
  "account": "UBS has reinstated coverage on IQVIA Holdings (NYSE:IQV) with an optimistic buy rating and has established a price target of $345.00, based on a report released on Tuesday. The company's stock is presently trading at $268.99, closely approaching its 52-week high of $277.40, after experiencing a 58% increase over the last six months. UBS's analysis indicates that the stock is currently undervalued in relation to its Fair Value. The investment bank asserts that the market is underappreciating the potential growth of book-to-bill metrics, which are projected to surpass 1.22x, consequently undervaluing the company's future growth rates and earnings.\n\nUBS highlights IQVIA's robust data infrastructure, which facilitates the realization of AI cost savings more efficiently than its competitors. The firm corroborates this assertion through dialogue with private contract research organizations, who confirm that book-to-bill activity is expected to improve in the forthcoming quarters. UBS's proprietary data on biotech funding reveals an impressive year-over-year surge of 87% on a trailing twelve-month basis, while pharmaceutical research and development is anticipated to expand at an annual rate of 5.2% in the long term. Furthermore, UBS's channel checks and sponsor survey suggest that IQVIA is likely to gain market share from its rival companies.\n\nBy employing a reverse discounted cash flow analysis, UBS determines that the market presently factors in a revenue growth range of 4% to 5% and a flat annual margin expansion of 15 basis points over a 10-year period. This forecast assumes an enterprise value to EBITDA exit multiple of around 14 times in 2036. For a comprehensive understanding, IQVIA is included in InvestingPro Research Reports, which encompass over 1,400 US equities. These reports convert intricate Wall Street data into practical intelligence.\n\nRecent updates from IQVIA Holdings include a $2 billion offering of senior notes due in 2034, which provides the company with substantial additional funds. These notes, issued by IQVIA Inc., a wholly-owned subsidiary, bear an interest rate of 6.375% annually. Notably, other industry experts have expressed confidence in IQVIA's future prospects. For instance, RBC Capital has elevated its price target to $319, pointing to accelerating new drug approvals as a growth driver. Truist Securities has likewise boosted its target to $329, emphasizing strong industry demand and increasing biotech activity. Stifel, too, has increased its target to $276, citing improved market conditions and IQVIA's enhanced market positioning. These analyst assessments reinforce a favorable outlook for IQVIA's performance and market standing.",
  "summary": null,
  "key_points": [
    "UBS reinstates coverage on IQVIA with buy rating",
    "Price target set at $345.00 based on book-to-bill outlook",
    "IQVIA's data infrastructure enables AI cost savings efficiently"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}